Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04156100 · ClinicalTrials.gov registry record · Phase 1
A Study in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04156100: Clinical Trial Phase 1 study, sponsored by Agenus.
NCT04156100 is a Phase 1 study that was terminated before completion, run by Agenus. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04156100, a Phase 1 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors.
Primary Outcome
In subjects in dose escalation
Interventions
- DRUG AGEN1223
- DRUG AGEN1223 and balstilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2021-09-29 |
| Phase | Phase 1 |
Why NCT04156100 stopped before completion
NCT04156100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which AGEN1223 is the first listed.
NCT04156100 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04156100 about?
NCT04156100 is a clinical study titled "A Study in Subjects With Advanced Solid Tumors". This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination...
What is the current status of trial NCT04156100?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-12-10. Estimated completion is 2021-09-29.
What interventions are being tested in trial NCT04156100?
The interventions under investigation include: AGEN1223 (DRUG), AGEN1223 and balstilimab (DRUG).
Who is sponsoring clinical trial NCT04156100?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04156100's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI